## SENTARA COMMUNITY PLAN (MEDICAID)

## MEDICAL PRIOR AUTHORIZATION/STEP-EDIT REQUEST\*

<u>Directions:</u> The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; <u>fax to 1-844-305-2331</u>. No additional phone calls will be necessary if all information (<u>including phone and fax #s</u>) on this form is correct. <u>If information provided is not complete</u>, correct, or legible, authorization can be delayed.

<u>Drug Requested</u>: Cosentyx® (secukinumab) IV (J3247/C9166) (Medical)

☐ Active Non-Radiographic Axial

**□** Active Psoriatic Arthritis

objective signs of inflammation

Spondyloarthritis (nr-axSpA) – with

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.				
Member Name:				
Member Sentara #:	Date of Birth:			
Prescriber Name:				
Prescriber Signature:				
Office Contact Name:				
Phone Number:	Fax Number:			
DEA OR NPI #:				
DRUG INFORMATION: Authorization may be delayed if incomplete.				
Drug Form/Strength:				
	Length of Therapy:			
Diagnosis:	ICD Code, if applicable:			
Weight:	Date:			
Standard Review. In checking this box, the timeframe does not jeopardize the life or health of the member or the member's ability to regain maximum function and would not subject the member to severe pain.				
• Cosentyx 125 mg/5mL solution; 1ml vial and 5ml vial = 125 billable units				
Cosentyx® is available under both Medical and Pharmacy benefits.				
DIAGNOSIS	Recommended Dose			
☐ Active Ankylosing Spondylitis	• With a loading dosage: 6 mg/kg given at Week 0 as a			

(Continued on next page)

infusion)

loading dose, followed by 1.75 mg/kg every 4 weeks

Without a loading dosage: 1.75 mg/kg every 4 weeks

thereafter (max. maintenance dose 300 mg per

(max. maintenance dose 300 mg per infusion)

**CLINICAL CRITERIA:** Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

Presc	eriber is: 👊 Dermatolog	gist 🗆 Rhe	eumatologist		
□ Diagnosis: Active Ankylosing Spondylitis					
	Trial and failure of at least two (	2) NSAIDs			
	<u>OR</u>				
	Use of NSAIDs is contraindicate	ed in patient			
	AND				
	Trial and failure of methotrexate				
	<u>OR</u>				
	Medication requested will be used in conjunction with methotrexate				
	<u>OR</u>				
	Patient has a contraindication to methotrexate (e.g., alcohol abuse, cirrhosis, chronic liver disease, or other contraindication)				
	AND				
	Trial and failure of <b>TWO (2)</b> of the <b>PREFERRED</b> drugs below (check each tried):				
	□ Humira <sup>®</sup>	□ Enbrel <sup>®</sup>	□ Infliximab		
□ Diagnosis: Non-Radiographic Axial Spondyloarthritis					
	Member has a diagnosis of Active Non-radiographic Axial Spondylarthritis (nr-axSpA) with objective signs of inflammation.				
□ Diagnosis: Active Psoriatic Arthritis					
	Trial and failure of methotrexate				
	<u>OR</u>				
	Medication requested will be used in conjunction with methotrexate				
	<u>OR</u>				

(Continued on next page)

	☐ Patient has a contraindication to methotrexate (e.g., alcohol abuse, cirrhosis, chronic liver disease, or other contraindication)					
	AND					
	Trial and failure of <u>TWO (2)</u> of the <u>PREFERRED</u> drugs below (check each tried):					
	☐ Humira <sup>®</sup>	□ Enbrel <sup>®</sup>	□ Infliximab			
		L				
Medication being provided by: Please check applicable box below.						
	cation/site of drug administrati	on:				
NPI or DEA # of administering location:						
OR						
□ Specialty Pharmacy – Proprium Rx						
_						
For urgent reviews: Practitioner should call Sentara Health Pre-Authorization Department if they believe a standard review would subject the member to adverse health consequences. Sentara Health's definition of urgent						
is a lack of treatment that could seriously jeopardize the life or health of the member or the member's ability to						
regain maximum function.						
**Use of samples to initiate therapy does not meet step edit/ preauthorization criteria. **						

\*Previous therapies will be verified through pharmacy paid claims or submitted chart notes. \*